MYCN Amplification in RB1 ‐Inactivated Retinoblastoma: Association With High‐Risk Features

Read full text Summarise with VIRAT
Authors: Kyriaki Papaioannou, Regina Kubica, Karen Fischhuber, Jasmin Beygo, Madlen Reschke, Petra Ritter‐Sovinz, Eva Maria Biewald, Petra Ketteler, Dietmar Rudolf Lohmann, Deniz Kanber
Cited by: 0
References: 30

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: MYCN amplification occurs in a subset of retinoblastoma cases, both with and without RB1 inactivation. It has been suggested that retinoblastomas with MYCN amplification represent a distinct entity with more aggressive clinical behavior. METHODS: We examined the incidence of MYCN gain/amplification and RB1 inactivation in 192 unilateral retinoblastoma samples from children enucleated between 2011 and 2018 at the German reference center. MYCN copy number was assessed using quantitative PCR and confirmed by single nucleotide polymorphism microarray analysis. Clinical characteristics, RB1 mutation status, and histopathological features were compared between MYCN-amplified and nonamplified retinoblastomas. RESULTS: ). The RB1 mutation spectrum and overall genomic copy number changes were similar between MYCN-amplified and MYCN-nonamplified retinoblastomas. Age at diagnosis did not differ significantly between the two groups (p = 0.21); however, secondary glaucoma, massive choroidal, and scleral invasion occurred more often in MYCN-amplified retinoblastomas (p = 0.038, p = 0.03, and p = 0.04, respectively). No cases of extraocular retinoblastoma or distant metastasis were observed during a median follow-up of 50 months. CONCLUSION: MYCN gain/amplification was identified in 7.2% of enucleated unilateral retinoblastomas, all of which showed RB1 inactivation. MYCN amplification was associated with more advanced disease and more aggressive clinical and histopathological features.

Fields of Study & Subjects

Ocular Oncology and Treatments Retinal Development and Disorders Ocular Disorders and Treatments

Publication details

Journal / source
Pediatric Blood & Cancer
Volume
73
Issue
6
Pages
e70297–e70297
Publication date
2 April 2026
Language
EN